Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of oxaliplatin and etoposide in
treating young patients with recurrent or refractory solid tumors or lymphomas. Drugs used in
chemotherapy, such as oxaliplatin and etoposide, work in different ways to stop the growth of
cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may
also help etoposide work better by making cancer cells more sensitive to the drug. Giving
oxaliplatin together with etoposide may kill more cancer cells.